MEB Stock Chart & Stats
€23.72
€0.50(2.03%)
At close: 4:00 PM EDT
€23.72
€0.50(2.03%)
Day’s Range― - ―
52-Week Range€19.49 - €37.82
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€826.89M
Enterprise Value€731.65
Total Cash (Recent Filing)€84.82M
Total Debt (Recent Filing)€57.41M
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Dec 08, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.91
Shares Outstanding35,924,610
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.68
Price to Book (P/B)264.15
Price to Sales (P/S)41.46
P/FCF Ratio-30.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€35.00Price Target Upside47.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.02
Revenue Forecast (FY)€47.65M
Bulls Say, Bears Say
Bulls Say
UZEDY Royalty GrowthRapid UZEDY sales growth is converting into expanding royalty income, strengthening MedinCell’s recurring revenue base. Continued prescription growth and the broader bipolar I label support a durable commercial contribution while reducing reliance on development-stage payments.
Olanzapine LAI Regulatory ProgressAcceptance of the olanzapine LAI NDA and the European filing materially advance a potential second royalty-generating product. The formulation’s reported clinical safety experience could support differentiation, although commercialization still depends on approval and launch execution.
Expanding Partnered PipelineA broad formulation-stage pipeline and multiple partner-funded programs create several potential future milestones and royalty streams. Progress with AbbVie and internal programs shows the BEPO platform is being extended beyond one marketed product, supporting longer-term growth optionality.
Bears Say
Persistent Losses And Cash BurnLarge operating losses and renewed cash consumption show that commercial royalty growth has not yet offset the cost of development and expansion. Sustained burn can increase funding sensitivity and constrain strategic flexibility before later-stage products contribute materially.
Milestone-driven Revenue VolatilityRevenue remains exposed to the timing of one-off milestone payments, making reported results uneven even as underlying royalty income improves. This volatility can complicate planning and leaves near-term performance dependent on contractual development achievements.
Dependence On Partner ExecutionMedinCell’s partnered model provides access to commercialization capabilities but also limits direct control over launches, promotion and development timing. Delays or conservative decisions by partners could defer royalties, milestones and the expected expansion of the platform.
MedinCell SA News
MEB FAQ
What was MedinCell SA’s price range in the past 12 months?
MedinCell SA lowest stock price was €19.49 and its highest was €37.82 in the past 12 months.
What is MedinCell SA’s market cap?
MedinCell SA’s market cap is €826.89M.
When is MedinCell SA’s upcoming earnings report date?
MedinCell SA’s upcoming earnings report date is Dec 08, 2026 which is in 71 days.
How were MedinCell SA’s earnings last quarter?
MedinCell SA released its earnings results on Jun 16, 2026. The company reported -€0.45 earnings per share for the quarter, missing the consensus estimate of -€0.14 by -€0.31.
Is MedinCell SA overvalued?
According to Wall Street analysts MedinCell SA’s price is currently Undervalued.
Does MedinCell SA pay dividends?
MedinCell SA does not currently pay dividends.
What is MedinCell SA’s EPS estimate?
MedinCell SA’s EPS estimate is -0.22.
How many shares outstanding does MedinCell SA have?
MedinCell SA has 35,924,610 shares outstanding.
What happened to MedinCell SA’s price movement after its last earnings report?
MedinCell SA reported an EPS of -€0.45 in its last earnings report, missing expectations of -€0.14. Following the earnings report the stock price went down -0.443%.
Which hedge fund is a major shareholder of MedinCell SA?
Currently, no hedge funds are holding shares in DE:MEB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MedinCell SA
MedinCell S.A. specializes in pioneering diverse therapeutic treatments. At the core of its development lies BEPO, a cutting-edge technology that enables the creation of long-acting injectable pharmaceutical products. This system leverages a unique combination of proprietary copolymers and a biocompatible solvent to effectively dissolve or suspend active drug compounds. The company's advanced pipeline includes several key products: mdc-IRM, a subcutaneous injection currently in Phase III clinical trials for the treatment of schizophrenia; mdc-CWM, an intra-articular injection designed to address pain and inflammation; and mdc-TJK, another subcutaneous injection targeting schizophrenia, presently in preclinical development. MedinCell is also actively engaged in formulation research for additional product candidates. These encompass subcutaneous injections such as mdc-WWM for contraception, mdc-ANG for central nervous system-related conditions, mdc-ELK for depression, and mdc-GRT for organ transplant applications. Furthermore, the firm is investigating perineural injections like mdc-CMV for anesthesia and pain management, and mdc-NVA, also intended for pain relief. MedinCell S.A. maintains its headquarters in Jacou, France.
MEB Stock 12 Month Forecast
Average Price Target
€35.00
▲(47.55% Upside)